ADDC and AstraZeneca partner to foster novel drug development among academic research community
BALTIMORE, Sept. 10, 2015 /PRNewswire-USNewswire/ -- The Academic Drug Discovery Consortium (ADDC) announced today the second call for proposals from its partnership with AstraZeneca aimed at facilitating efforts by researchers from academia and institutions towards the discovery of novel compounds with potential pharmaceutical application. The goal of this partnership is to provide ADDC members with access to a high quality compound library, while allowing AstraZeneca the opportunity to collaborate with academic researchers in the hope of identifying novel disease targets and drugs across a wide range of therapy areas.
The institutions selected to participate in this project will receive access to up to 250,000 compounds from AstraZeneca's internal screening library. The compounds to be made available in this project are intended to provide a broad representation of AstraZeneca's industry-leading compound collection.
In order to be considered for this project, candidate institutions must be members of ADDC and respond through a Request for Proposals (RFP) process. Responses will be judged by a Technical Review Committee consisting of Astra Zeneca and ADDC members. AstraZeneca may provide financial or material support to selected projects.
The proposals selected this year will build on last year's success. Last year four proposals were selected from Brigham and Women's Hospital, the University of Lisbon, and the Johns Hopkins University.
Additional information on this project, eligibility requirements, and the Call for Proposals can be found at www.addconsortium.org. Proposals are due Oct 15, 2015. Proposals selected by the Technical Review Committee will be announced in late Fall 2015.
About the Academic Drug Discovery Consortium
ADDC is growing international consortium established in 2012 and currently comprises over 130 university-led drug discovery centers and over 1300 individual members from 41 countries. The ADDC mission is to nurture academic drug discovery centers in the rapidly changing environment and build a collaborative network to facilitate the exchange of expertise and technology know-how, and the formation of partnerships between each other and pharmaceutical industry. For more information, visit www.addconsortium.org or contact Dr. Barbara Slusher, founder and President of ADDC, and Director, Johns Hopkins Drug Discovery ([email protected]) or Matthew Hartman, Director, Business Development, ADDC ([email protected]).
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com or contact David Smith, Principal Scientist, AstraZeneca ([email protected]).
SOURCE Academic Drug Discovery Consortium
Share this article